On June 30, 2021, Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer's disease, announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to Acumen, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $160 million. The shares began trading on the Nasdaq Global Select Market on July 1 under the ticker symbol “ABOS." The offering closed on July 6.
The Wilson Sonsini team advising Acumen on IP matters related to the transaction was led by Julia Minitti and included Ying Chen, and Mike Hostetler.
For more information, please see Acumen's press release.